To describe the clinicopathological characteristics and prognosis of subsequent non-muscle-invasive bladder cancer (NMIBC) after radical nephroureterectomy (RNU) for upper urinary tract urothelial carcinoma (UTUC), and particularly its response to intravesical Bacillus Calmette-Gu erin (BCG).
Introduction
Upper urinary tract urothelial carcinoma (UTUC) is a rare malignancy and accounts for only 5-10% of urothelial carcinoma (UC) [1] . Radical nephroureterectomy (RNU) with excision of the bladder cuff is currently the 'gold standard' treatment for localized UTUC [2] ; however, this malignant disease can present various clinical courses including local recurrence, distant metastasis, lymph node involvement and intravesical recurrence after RNU. Previous epidemiological studies have shown that 15-50% of patients who undergo RNU experience intravesical recurrence during the follow-up [3] . Yamashita et al. [4] reported that the majority of recurrent intravesical tumours develop in the bladder mucosa around the site of the bladder cuff within 1 year of RNU. Several studies conducted to find the clinicopathological risk factors for intravesical recurrence have suggested an association with multiplicity, tumour size, T category and tumour grade of the primary UTUC, and the use of diagnostic ureteroscopy [3] [4] [5] [6] .
Intravesical instillation of bacillus calmette-guerin (BCG) is a standard treatment for carcinoma in situ (CIS) and an adjuvant option for T1 and higher grade Ta bladder tumours after transurethral resection of bladder tumour (TURBT) [7] . Evidence from studies on primary non-muscle-invasive bladder cancer (NMIBC) has led to risk stratification and treatment guidelines for primary NMIBC [8] [9] [10] [11] ; however, little is known about subsequent NMIBC after RNU for primary UTUC (hereafter referred to as UTUC-NMIBC). Although bladder UC and UTUC have many similarities, there are several anatomical, biological and molecular differences that warrant consideration of these conditions as two distinct urothelium-derived malignancies [12, 13] .
In view of the sparse data on the oncological outcomes of UTUC-NMIBC, the present collaborative study was conducted to evaluate its clinical characteristics, prognosis and response to BCG with the ultimate goal of improving the care we deliver to our patients.
Materials and Methods
Study Cohort: Patients with NMIBC after RNU As a multicentre study with our collaborative groups in the Western region of Japan, the present study was approved by the institutional review board of each participating institute (reference ID: 1298 and 1487). We retrospectively reviewed our cohort of 1438 patients who underwent RNU for pathologically diagnosed UTUC between 1994 and 2015 in our collaborative hospitals. The main tumour location of the 1438 UTUCs was the renal pelvis in 642 (44.6%), the ureter in 672 (46.7%), and the renal pelvis and ureter in 113 patients (7.8%), and was unknown in 11 patients (1%). The surgical procedure for RNU and the postoperative follow-up protocol have been described in our previous report [1] . Intravesical recurrence after RNU was defined as an intravesical tumour which was pathologically confirmed as UC.
The cohort was first restricted to 1171 of the 1438 patients, by including only those with no previous and/or concurrent history of bladder cancer, to avoid a potential bias. Of these 1171 patients, 444 (38%) were found to have recurrent bladder UC after RNU during the follow-up, while 727 (62%) were not. After excluding patients who had muscle-invasive bladder cancer at the initial bladder cancer recurrence after RNU or did not have critical data, such as T category, tumour grade and follow-up information, 256 patients were finally eligible for inclusion in the present investigation. These patients were grouped based on whether they had received the adjuvant intravesical BCG after TURBT or not (Fig. 1) . Clinicopathological characteristics of the patients, including age, sex, tumour shape (papillary or non-papillary), multiplicity (solitary or multiple), T category, tumour grade (the 1973 and 2004 WHO classification), presence of CIS, adjuvant intravesical treatment, and prognosis after initial TURBT were all obtained from the medical charts.
Control Cohort: Patients with Primary Bladder NMIBC
In addition to the UTUC-NMIBC cohort, we also prepared a database of 1555 patients with primary NMIBC who were treated between 1990 and 2015 at the same collaborative hospitals. Of the 1555 patients, 352 (23%) who received adjuvant intravesical treatment after TURBT were selected to form the control cohort (Fig. 1) . The same clinicopathological characteristics were obtained from the medical charts to compare with the UTUC-NMIBC cohort.
Adjuvant Intravesical Therapy for NMIBC after TURBT
Being a retrospective multicentre collaborative study, the criteria, dosage and scheme for adjuvant intravesical therapy were not consistent and depended on the physician's decision. In general, patients with high-risk NMIBC, such as those positive for concomitant CIS, T1 category, and high grade tumours, were treated with intravesical BCG. A substantial number of patients were given intravesical BCG as initial adjuvant therapy. The schedule for intravesical BCG consisted of weekly instillations for 6-8 consecutive weeks of Immunobladder (BCG Tokyo 172 strain; Japan BCG Laboratory Tokyo, Japan) or ImmuCyst (Connaught strain; Sanofi, Paris, France; no longer supplied as of September 2017). A single immediate post-TURBT chemotherapy instillation and/or maintenance chemotherapy instillation were given to a subset of the cohort. The schedule for maintenance instillation chemotherapy consisted of weekly instillations for 6-30 consecutive weeks. The doses of chemotherapy drugs were 20-40 mg epirubicin, 20-30 mg pirarubicin, or 30-40 mg mitomycin C.
Calculation of the CUETO Scoring Model
Recurrence and progression scores were calculated according to the Club Urol ogico Español de Tratamiento Oncol ogico (CUETO) risk model, which uses age, sex, previous recurrence, tumour stage, tumour grade (1973 WHO classification), tumour size, multiplicity and the presence of concomitant CIS as factors. Because the cohorts consisted of patients diagnosed with both primary NMIBC as well as initial intravesical recurrence after RNU, the score for 'previous recurrence' was set to 0 for all patients. Patients with isolated Tis (no Ta/T1 tumour) were excluded from the analysis because the CUETO scoring model was developed exclusively for Ta and T1 tumours.
Statistical Analysis
The clinicopathological characteristics were compared using Student's t-test, the chi-squared test, and analysis of variance as appropriate. Intravesical recurrence-free survival, bladder progression-free survival, and bladder UC-specific survival were calculated from the date of TURBT for the initial intravesical recurrence after RNU to the date of second intravesical recurrence, progression to carcinoma invading the bladder muscle, and death from the progression of bladder UC, respectively. Bladder progression was defined as the development of carcinoma invading the bladder muscle from NMIBC because radiographic imaging of lymph nodes, and visceral metastasis could not differentiate between UTUCderived and bladder UC-derived lesions. Survival rates were analysed using the Kaplan-Meier method and compared using the log-rank test for univariate analysis. PRISM software version 5.00 (San Diego, CA, USA) was used for statistical analyses and plotting of data. Statistical significance in this study was set at P < 0.05 and all reported P values are twosided.
Because of the differences in baseline characteristics between the UTUC-NMIBC and control primary NMIBC cohorts, we carried out a propensity score-matched analysis to adjust for those differences [14] . The propensity score was calculated for each patient using a multivariable logistic regression model based on sex, age at initial TURBT, T category, tumour grade, the presence of CIS, tumour shape, and multiplicity of bladder UC. All of these variables are known to be prognostic factors for bladder UC [8] [9] [10] . A 1:1 matching ratio was used to maintain a large sample size, which maximized the power while maintaining a balance between the two groups. EZR (Easy R) statistical software was used for the multivariable logistic regression analysis and propensity score matching [15] .
Results

Characteristics of Patients with UTUC-NMIBC
Of the 1171 patients with UTUC with no previous and/or concurrent history of bladder cancer, 444 (38%) experienced subsequent bladder UC during the follow-up after RNU. The median time to the initial intravesical recurrence was 9.1 months (Fig. S1 ). After applying exclusion criteria to these 444 patients, 256 patients (58%) were eligible for the analysis. Adjuvant intravesical treatment depended on the physicians decision based on the clinicopathological characteristics of the patients at the time of TURBT. While 75 patients (29%) received intravesical BCG, 181 (71%) did not. Table 1 lists the patient characteristics, survival data and the statistical comparison between the BCG-treated patients and those who did not receive the treatment. A higher incidence of high-grade tumours and positive CIS was noted among the BCG-treated patients compared with the patients who did not receive BCG. While the intravesical recurrencefree survival rates were similar in the two groups, no significant trends were observed in the bladder progressionfree survival and bladder UC-specific survival (Fig. S2 ). Table 2 summarizes the patient characteristics before and after propensity score matching. Risk factors such as sex, T category, and tumour multiplicity for the UTUC-NMIBC (n = 75) and primary NMIBC (n = 352) groups were significantly different before the propensity score matching. There was only a marginal difference (P = 0.07) in tumour shape, which is reported to be a risk factor for NMIBC [10] . Adjustment using propensity score matching resulted in an even distribution of the patient baseline characteristics in the UTUC-NMIBC (n = 75) and primary NMIBC (n = 75) groups.
Among the BCG-treated patients, during the follow-up, a second intravesical recurrence was observed in 35 (47%) of 75 patients in the UTUC-NMIBC group and in 104 (30%) of 352 patients in the primary NMIBC group. Bladder progression was observed in 12/75 (16%) and 29/352 patients (8%) in the UTUC-NMIBC and primary NMIBC groups, respectively. Bladder UC-specific death occurred in 7/75 (9%) and 16/352 patients (5%) in the UTUC-NMIBC and primary NMIBC groups, respectively. Survival curve comparison showed significant differences in the assessment of three endpoints ( Fig. 2A) . After the adjustment, patients with UTUC-NMIBC had a worse intravesical recurrence-free survival rate compared with patients with primary NMIBC (Fig. 2B, left panel) , but there were no significant differences between the two groups with regard to bladder progressionrelated survival and death (Fig. 2B , two panels on right).
Risk Stratification and Validation by the CUETO Scoring Model
The latest guidelines from the European Association of Urology (EAU), updated in 2016, recommend the use of CUETO risk tables to predict the risk of intravesical recurrence and progression in patients treated with intravesical BCG. To examine the clinical utility of the CUETO scoring model for patients with UTUC-NMIBC treated with intravesical BCG, scores were calculated and compared with the outcome. The mean recurrence score (AESD) of UTUC-NMIBC, unadjusted primary NMIBC, and adjusted primary NMIBC groups were 6.4 AE 3.1, 5.9 AE 2.8, and 6.7 AE 3.1, respectively (Fig. 3A) . In each cohort, 50-60% of patients were assigned to low-risk groups (scores of 0-4 and 5-6; Fig. 3B ). We also performed a categorical analysis of the 0-4, 5-6, 7-9 and 10-16 recurrence scoring groups. The mean progression scores for the UTUC-NMIBC, unadjusted primary NMIBC and adjusted primary NMIBC groups were 5.9 AE 3.5, 6.9 AE 3.5 and 6.6 AE 3.6, respectively (Fig. 3C) . Although the progression score for the unadjusted primary NMIBC group was higher than that for the UTUC-NMIBC group, there was no significant difference between UTUC-NMIBC and adjusted primary NMIBC groups. Additional categorical analysis of the 0-4, 5-6, 7-9 and 10-14 progression scoring groups yielded results similar to those of continuous analysis (Fig. 3D ).
The probabilities of recurrence and progression for patients in the UTUC-NMIBC, unadjusted primary NMIBC, and adjusted primary NMIBC groups at 1, 2 and 5 years are shown in Table 3 . A higher score tended to be associated with poor prognosis. The 0-4 group of patients with UTUC-NMIBC was observed to have a much higher recurrence rate as compared with patients in the primary NMIBC group. Their recurrence rate was also higher than the rate predicted in the CUETO risk table. The recurrence rate of the higher risk groups (scores of 7-9 and 10-16) was similar to that in the CUETO risk table. In addition, the comparison between the three cohorts showed that the higher risk groups in the UTUC-NMIBC cohort had a higher recurrence rate than the cohorts with primary NMIBC. The 2-year and 5-year progression rates for the UTUC-NMIBC group were higher than the values presented in the CUETO risk tables (Table 3) . Most of the remaining subsets of the three cohorts had lower probabilities of progression than those predicted by the CUETO risk table.
Discussion
The present study shows that patients with UTUC-NMIBC are more likely to develop intravesical recurrence after receiving intravesical BCG as compared with patients with primary NMIBC. This finding suggests that patients with UTUC-NMIBC have a poor response to BCG. Although our findings need to be validated, to our knowledge, this is the first study showing poor outcomes in patients with UTUC-NMIBC using a propensity score-matched cohort of patients with primary NMIBC, both groups having received intravesical BCG. The development of bladder tumour after RNU often occurs at a rate ranging from 15% to 50% [1, 3] , yet its clinical features have not been well described as compared with primary bladder cancer. Our previous report investigated the changes in oncological outcomes over the last two decades using a multicentre based-database of >1000 patients with UTUC [1] . In addition to our UTUC database, the clinicopathological data on patients with primary NMIBC treated with intravesical BCG as the control cohort were extracted from a multicentre database of >1500 patients. Risk factors linked to intravesical recurrence after RNU are well documented in previous studies. The available information including a meta-analysis of significant predictors of intravesical recurrence proposes a risk-adapted approach to adjuvant intravesical chemotherapy and cystoscopic surveillance after RNU [3] [4] [5] [6] 16] . Two prospective randomized clinical trials have shown that the removal of any disseminating tumour cells using an immediate single intravesical treatment with mitomycin C or pirarubicin after RNU decreased the risk of intravesical recurrence [17, 18] . The most recent EAU guidelines also advocate this strategy [2] ; however, the focus of the present study was to investigate the clinical outcomes in patients with UTUC-NMIBC, especially their response to intravesical BCG, using a propensity score-matched cohort with primary bladder cancer. (Table 1) . Of the 181 patients, no less than 43% (78 patients) and 52% (94 patients) had T1 and high-grade tumours, respectively. These patients with high-risk disease might require adjuvant intravesical BCG if we comply with treatment guidelines for NMIBC. Most of the decisions regarding the clinical management of UTUC are based on extrapolations from data on bladder UC cohorts because of the preponderance of bladder UC; however, we believe that because bladder UC originates from the upper urinary tract, it differs substantially from the primary bladder UC in terms of its clinical behaviour, course and biological characteristics, although there are significant similarities too. The current NMIBC guidelines may therefore be inadaptable to UTUC-NMIBC. Yates et al. [13] highlighted the utility of molecular markers in the diagnosis and management of UTUC by focusing on how UTUC differs from bladder UC. They reported significant differences in the genetic (microsatellite instability) and epigenetic (hypermethylation) backgrounds of the two diseases [13] .
The limitations of clinical studies on UTUC include their relatively small sample sizes as a result of UTUC being a rare tumour. In the present study, we used a large, multicentre series to analyse the clinical outcomes of UTUC-NMIBC in comparison with primary NMIBC. Although the present study is based on retrospective analysis, observational studies can provide real-world comparative effectiveness data. Propensity score matching is a common and useful technique used in observational studies to select control subjects who are matched with studied subjects on controlled background covariates to reduce biases to a minimum [14] . Because clinical trials are difficult to implement in the current clinical situation, this propensity score-matched analysis was introduced to adjust the control cohort for confounding variables when comparing the outcomes between UTUC-NMIBC and primary NMIBC after intravesical BCG (Fig. 2) . The CUETO risk stratification showed that there were no significant differences in the recurrence scores for UTUC-NMIBC and unadjusted primary NMIBC/adjusted primary NMIBC. The intravesical recurrence-free survival rate for UTUC-NMIBC was significantly lower than that for primary NMIBC, even after background adjustment. This finding suggested that the recurrent potential of UTUC-NMIBC after intravesical BCG was higher than that of primary NMIBC, implying that the former has a higher resistance to BCG treatment. The progression score for unadjusted primary NMIBC was higher than that for UTUC-NMIBC. Although adjustment of the primary NMIBC cohort decreased the progression score from 6.9 AE 3.5 to 6.6 AE 3.6, the progression rate increased slightly (Table 3) , resulting in similar progression-free survival for both UTUC-NMIBC and adjusted primary NMIBC. Although difficult to explain, this finding can be partly attributed to the fact that the scoring model does not work perfectly for all cohorts.
The CUETO scoring model and the European Organization for Research and Treatment of Cancer (EORTC) risk table are currently the two best-established predictive tools to help make decisions for patients with NMIBC [8, 9] . To date, several reports have attempted to validate the risk tables using independent cohorts to aid in the prediction of outcomes [10, 19, 20] . The Department of Urology, Yamaguchi University participating in this collaborative study previously Because the CUETO model was based on data from patients receiving BCG instillation therapy, the EAU guideline recommends the use of the CUETO risk tables to predict the risk of intravesical recurrence and progression in patients treated with intravesical BCG. We found a significant difference in the intravesical recurrence rates for the 0-4 and 5-6 groups in UTUC-NMIBC and the rate shown in the CUETO risk table (Table 3) . Thus, the CUETO scoring model was not reliable in the subset of patients with UTUC-NMIBC treated with intravesical BCG. A new scoring model specific to UTUC-NMIBC needs to be established to improve the care we deliver to our patients.
The present study has several limitations. The first is its retrospective nature with potential selection bias; for example, some patients were excluded because they received aggressive treatment (immediate radical cystectomy for T1 disease) or had insufficient data. Second, a relatively small number of patients with UTUC-NMIBC were enrolled in this analysis. In addition, the studied cohort was from multiple institutions, which could introduce inconsistencies in surgical skills, follow-ups, clinical interpretations and pathological diagnosis.
In conclusion, the UTUC-NMIBC group had a worse prognosis with a higher intravesical recurrence rate after intravesical BCG when compared with the primary NMIBC group, suggesting that this group comprises inherently poor responders to BCG. There are anatomical, biological and molecular differences that should be considered for risk stratification and treatment of patients with the disparate twin diseases, UTUC-NMIBC and primary NMIBC. An optimum treatment strategy and risk scoring model for selecting patients for adjuvant intravesical BCG, chemotherapy or immediate radical cystectomy should be established. To overcome the challenges that impede progress toward evidence-based medicine in UTUC, we need to make extra efforts in identifying the potential strategies for better patient outcomes.
